Venclexta and Armour thyroid drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Venclexta (venetoclax) and Armour thyroid (thyroid tablets, usp). Common drug interactions include death among females and white blood cell count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Venclexta and Armour thyroid. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Venclexta?

Venclexta has active ingredients of venetoclax. eHealthMe is studying from 31,425 Venclexta users. Check the latest studies of Venclexta.

What is Armour thyroid?

Armour thyroid has active ingredients of thyroid tablets, usp. It is often used in hypothyroidism. eHealthMe is studying from 11,975 Armour thyroid users. Check the latest studies of Armour thyroid.

On Jul, 31, 2026

13 people who take Venclexta and Armour thyroid together, and have interactions are studied.

Venclexta and Armour thyroid drug interactions.

What are the common drug interactions of Venclexta and Armour Thyroid, by gender? *:

female:

Death
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
Blood phosphorus increased
Blood potassium increased
Diarrhoea
Fatigue (feeling of tiredness)
Herpes virus infection
Pancreatic carcinoma (pancreatic cancer)

male:

White blood cell count decreased
Anaemia (lack of blood)
Vitamin d increased
Dyspnoea (difficult or laboured respiration)
Infection
Asthenia (weakness)
Balance disorder
Blood creatinine decreased
Chronic lymphocytic leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell))
Dehydration (dryness resulting from the removal of water)

What are the common drug interactions of Venclexta and Armour Thyroid, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Death
Dyspnoea (difficult or laboured respiration)
Dizziness
Ear discomfort
Limb injury
Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)
Nasopharyngitis (inflammation of the nasopharynx)
Procedural pain
Respiratory tract congestion (blockage on respiratory system)
Infection

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 7 people, 53.85%
Nausea (feeling of having an urge to vomit): 2 people, 15.38%
Multiple Myeloma (cancer of the plasma cells): 2 people, 15.38%
High Blood Pressure: 2 people, 15.38%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 15.38%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 15.38%
Sleep Disorder: 1 person, 7.69%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 1 person, 7.69%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 7.69%
Lymphocytic Leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Venclexta and Armour thyroid?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously